Biomodulation induced by fluorescent light energy versus standard of care in venous leg ulcers: a retrospective study

Abstract

Objective: The recently completed EUREKA study confirmed the efficacy and safety profile of fluorescent light energy (FLE) in treating hard-to-heal wounds. To supplement the EUREKA prospective, observational, uncontrolled trial results, researchers selected one of the EUREKA clinical centres to conduct a retrospective analysis of matching wound care data for 46 venous leg ulcers (VLU) patients who had received standard wound care over a five-year period, compared with 10 EUREKA VLU subjects. Method: The study centre selected 46 patients with VLUs based on the matching criteria (wound age and size, patient's age and gender). They compared the healing rates of these matching VLUs with 10 VLU patients treated at the same centre during the EUREKA study. Results: The EUREKA patients had larger and significantly older wounds (p<0.05) and significantly more risk factors (p<0.05) than the matching wounds. However, they had better outcomes (EUREKA: 40% versus matching group: 7% for full wound closure by 16 weeks). No wound breakdown was observed at 16 weeks in the EUREKA group, compared with 25% in the matching group. No EUREKA patient developed infections requiring antibiotics, compared with 37% in the matching group. EUREKA wounds had a mean relative wound area regression (RWAR) of 32% at week six and 50% at week 16, compared with −3% at week six and −6% at week 16 for the matching group. Conclusion: These findings show that the system based on FLE was well-tolerated and efficacious, with better clinical outcome results compared with the wounds analysed in this retrospective matching study and treated with standard of care alone.

Updates on Recent Clinical Assessment of Commercial Chronic Wound Care Products

“…Also, the mean relative wound area regression (RWAR) was 32% (6 weeks) and 50% (16 weeks) as compared to the matching group (wound age, size, patient's age, and gender), which is −3% and −6% for 6 and 16 weeks, respectively. [137] NATROX oxygen wound therapy is a class II, novel, one-timeuse medical device. It constitutes i) a portable, reusable oxygen generator with a rechargeable battery and ii) a proprietary wheelshaped oxygen delivery system (ODS).…”

“…Also, the mean relative wound area regression (RWAR) was 32% (6 weeks) and 50% (16 weeks) as compared to the matching group (wound age, size, patient's age, and gender), which is −3% and −6% for 6 and 16 weeks, respectively. [ 137 ]…”

Fluorescent Light Energy (FLE) Acts on Mitochondrial Physiology Improving Wound Healing

“…To generate fluorescence, specialized chromophores (light absorbing molecules) are employed to translate light energy into a low-energy emission of fluorescence through a mechanism known as stokes shift [36]. FLE is a unique form of photobiomodulation that has been demonstrated to advance healing of both acute and chronic wounds [37,38]. Studies have demonstrated that acute incisional wounds have reduced inflammation, as well as more physiologic re-epithelization and collagen remodeling resulting in better quality and less visible scars [25][26][27]39].…”